ArticleMaedica2025
Prognostic Significance of Mast Cell Count and Angiogenesis in Central Giant Cell Granulomas of the Jaws.
Article in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mast cells (MCs) secrete different angiogenic factors stimulating angiogenesis. The purpose of this study was to assess MC count and microvessel density (MVD) in aggressive and non-aggressive central giant cell granulomas (CGCGs) of the jaws. Materials and methods: Sixteen aggressive and 14 non-aggressive paraffin-embedded samples of CGCGs were prepared for immunohistochemical analysis using anti-MC tryptase and anti-CD31 antibodies. Results: Mean values±SEM (standard error of mean) for MC count and MVD in aggressive and non-aggressive CGCGs were: 7.48±0.84, 3.85±0.51, 5.55±0.89, 3.19±0.61, respectively. All CGCG cases demonstrated MCs. Differences for both MC count and MVD were statistically significant between aggressive and non-aggressive CGCGs (p=0.002 and p=0.045, respectively), i.e. , MC count and MVD were significantly higher in aggressive lesions. Moreover, there was a significant positive correlation between MC count and MVD in CGCG (r=0.570, p=0.001). Conclusion: Mast cell count and MVD might be used as prognostic markers of aggressive behavior of CGCGs at the time of initial biopsy. Our findings might postulate that therapeutic strategies against MC mediators and angiogenesis may benefit in aggressive CGCG as a non-surgical modality of treatment. With further studies, their prognostic significance and therapeutic application can be evaluated in patients suffering from aggressive CGCG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.